This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Nestle Plumps Up Skin Health with Valeant Deal

Stocks in this article: VRX AGN

NEW YORK (The Deal) -- Switzerland's Nestle SA is bolstering its recently created skin health division through a $1.4 billion deal to buy rights to dermatology treatments from Canada's Valeant Pharmaceuticals International (VRX).

The announcement on Wednesday coincided with news that Valeant had lifted its hostile offer for Botox maker Allergan (AGN) to $49.4 billion.

Valeant said the sale of what it called filler and toxin treatments including Restylane, Perlane, Emervel, Sculptra and Dysport to Nestle wasn't conditional on its bid for Irvine, Calif.-based Allergan bid succeeding.

Vevey, Switzerland-based Nestle plans to fold the skin treatments it is acquiring into its Nestle Skin Health SA division, which has at its core the Galderma dermatology company from which it is in the process of buying out partner L'Oreal.

The deal with Valeant gives Nestle full rights to commercialize the treatments in the U.S. and Canada. Galderma already sells the products outside those markets.

"With this deal we have acquired key strategic assets to extend Nestle's activities in the field of specialised, medical skin treatments, providing consumers with life-enhancing scientific products," said Nestle chairman Peter Brabeck-Letmathe in a statement.

"This move will reinforce Galderma's leading position in the industry when it becomes Nestle Skin Health by allowing it to complete its geographic footprint for its strong portfolio of brands and leading medical solutions globally," added Nestle CEO Paul Bulcke.

The transaction requires regulatory approval. Nestle's purchase of the outstanding 50% of Galderma has yet to receive all the needed regulatory approvals. Valeant noted that Nestle expects the Galderma buyout to close in July.

The February deal between Nestle and L'Oreal valued the French seller's 50% stake in Galderma at 3.13 billion ($4.26 billion), including 490 million of debt. It was part of a wider agreement under which L'Oreal agreed to buy and cancel 8% of its stock owned by Nestle in exchange for 6.5 billion in cash and assets, including the Galderma stake.

Nestle received financial advice from Credit Suisse Group's Jens Welter and legal counsel from Kevin Rinker, Jeff Cunard, Jon Lewis and Gary Friedman from Debevoise & Plimpton. Valeant received legal advice from Sullivan & Cromwell's Alison Ressler and Sarah Payne.

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!

Markets

DOW 18,030.21 +6.04 0.03%
S&P 500 2,081.88 -0.29 -0.01%
NASDAQ 4,773.4720 +8.0480 0.17%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs